PFG Investments LLC Raises Stock Position in OPKO Health, Inc. $OPK

PFG Investments LLC lifted its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 3.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,265,125 shares of the biotechnology company’s stock after buying an additional 47,765 shares during the quarter. PFG Investments LLC’s holdings in OPKO Health were worth $1,670,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oak Thistle LLC acquired a new position in shares of OPKO Health during the 1st quarter worth $26,000. GM Advisory Group LLC acquired a new position in shares of OPKO Health during the 1st quarter worth $33,000. Cerity Partners LLC acquired a new position in shares of OPKO Health during the 1st quarter worth $36,000. Pallas Capital Advisors LLC acquired a new position in shares of OPKO Health during the 1st quarter worth $43,000. Finally, Voleon Capital Management LP acquired a new position in shares of OPKO Health during the 1st quarter worth $45,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Price Performance

OPK opened at $1.55 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -6.20 and a beta of 1.50. The business has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.40. OPKO Health, Inc. has a 12 month low of $1.11 and a 12 month high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $156.80 million during the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The firm’s quarterly revenue was down 13.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.01) EPS. On average, research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the stock in a transaction on Friday, August 8th. The stock was bought at an average price of $1.32 per share, for a total transaction of $891,000.00. Following the acquisition, the chief executive officer directly owned 214,676,448 shares of the company’s stock, valued at $283,372,911.36. This represents a 0.32% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 49.69% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on OPK shares. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $2.63.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.